Thorkil Kastberg Christensen
Thorkil Kastberg Christensen joined SAB’s board in March of 2017 after serving for two years as a strategic international business advisor.
Christensen brings to SAB decades of global business strategy and execution as former Chief Financial Officer of Denmark-based Novo A/S, which invests and manages the assets of the Novo Nordisk Foundation valued at about 40 BN USD. He also established Novo Nordisk organizations around the world over two decades–as CEO of China and Vice President of International Operations. In these roles, he was responsible for building affiliates and businesses in 15 Eastern European and 12 Asian countries and participated in his early days in building businesses in North America and Europe as well.
In his early professional life, Christensen worked with immunology R&D, later on spent many years on commercial issues, and lately financing. As a proven leader in the life science business, he has specialized in internationalization, as well as mergers, and other transactions including building organizations–transforming research and development to commercial focus–and adding value to start-ups.
Since 2009, he has held board positions with private and publicly listed companies, in Denmark, abroad, and in public institutions including Chairman of the board of Danish-Chinese Business Forum, Jørgen Kruuse A/S and BioMimetics Inc., USA. In addition to his board seat with SAB, Christensen presently serves as a professional board member for Strategic Design Group and Sonion A/S among others.
Christensen holds a Masters of Science in Chemistry from Technical University of Denmark (DTU) and a Bachelor in Finance from Copenhagen Business School (CBS) as well as management, investment, private equity and BoD courses from Harvard, Stanford, Wharton, INSEAD and IMD.